Start here if you're new
what it is
McKesson moves medicines, medical supplies, and pharmacy software through the U.S. healthcare system at massive scale.
how it gets paid
Last year Mckesson made $359.1B in revenue. North American Pharmaceutical was the main engine at $301.6B, or 84% of sales.
why it's growing
Revenue grew 16.2% last year. Earnings seem poised to climb, as business momentum remains strong.
what just happened
Latest quarter EPS came in at $9.34 versus a $9.20 estimate.
At a glance
A balance sheet — strong enough to weather a downturn
95/100 earnings predictability — you can trust these numbers
21.4x trailing p/e — priced about right
0.5% dividend yield — cash in your pocket every quarter
45.3% return on capital — every dollar works hard here
xvary composite: 93/100 — above average
What they do
McKesson moves medicines, medical supplies, and pharmacy software through the U.S. healthcare system at massive scale.
Scale is the moat. North American Pharmaceutical is 84% of sales, or about $301.6 billion of trailing revenue based on $359.1 billion total revenue from EDGAR and segment mix from the company profile. In drug distribution, scale means buying power and logistics reach, which is plain English for getting the right drugs to the right place fast, so your customers keep coming back because switching is painful.
How they make money
$359.1B
annual revenue · their business grew +16.2% last year
North American Pharmaceutical
$301.6B
Oncology & Multispecialty
$39.5B
Medical-Surgical
$10.8B
Prescription Technology Solutions
$3.6B
Other and rounding
$3.6B
The products that matter
wholesale drug logistics
Pharmaceutical Distribution
$106.2B quarterly revenue flow
it moved $106.2B of revenue in the latest quarter, including $14B tied to GLP-1 weight-loss drugs alone. This is the scale engine.
core engine
cancer drug distribution & services
Oncology & Specialty Solutions
40% adjusted EPS jump
this business helped drive a 40% jump in adjusted EPS in the recent period. The quiet part: specialty drugs matter more to profits than their plain-vanilla distributor label suggests.
profit driver
pharmacy software & services
Prescription Technology Solutions
1/3 of U.S. scripts network
the snapshot is thin on standalone revenue here, which tells you this is support infrastructure more than headline segment. It still matters because it plugs into the same network handling roughly one-third of U.S. prescription volume.
stickier network
Key numbers
45.3%
return on capital
Jargon → return on capital → profit earned on the money used in the business → so what: McKesson turns a low-margin model into a very efficient one.
$359.1B
annual revenue
This is scale in plain English. McKesson moves more healthcare dollars in a year than most companies see in a decade.
2.0%
operating margin
That thin margin explains the business. Tiny spread, huge volume, no room for sloppiness.
$48.00
fy2027 eps est
If the company reaches this estimate from $38.36 trailing EPS, your earnings base is still climbing even after a big stock run.
Financial health
A
strength
- balance sheet grade A — very strong financial position
- risk rank 1 — safer than 95% of stocks
- price stability 95 / 100
- long-term debt $6.0B (6% of capital)
- net profit margin 1.2% — keeps 1 cents of every dollar in revenue
A — among the top-rated companies for balance sheet quality.
Total return vs. market
You invested $10,000 in MCK 3 years ago → it's now worth $21,840.
The index would have given you $14,770.
source: institutional data · total return
What just happened
beat estimates
Latest quarter EPS came in at $9.34 versus a $9.20 estimate.
Revenue was about $106.2B in the quarter, according to Reuters and earnings coverage, while gross margin was 3.4% from EDGAR. Management also raised fiscal 2026 profit guidance, which is the part the market actually cared about.
$106.2B
revenue
$9.34
eps
3.4%
gross margin
the number that mattered
The key number was $9.34 in EPS because McKesson only makes a small margin on each revenue dollar, so earnings execution is the whole story.
-
mckesson has given investors plenty to smile about, and its stock has reached yet a new high.
-
since early november, shares of the medical supplies/ services provider have risen another 10% in value, thanks mostly to strong operating results and an upbeat near-term outlook.
-
while sales in the fiscal 2025 second quarter (ended september 30th) missed the mark (of $104.5 billion), they still rose 10%, vs. prior year, to a record level.
-
more impressive, adjusted share profits soared 40%, blowing past estimates of $8.90.the core north american pharmaceutical arm again did well, on higher script volume from retail national account customers, while the oncology & multispecialty unit saw outsized gains from the distribution of cancer and multispecialty products and recent acquisitions.
-
earnings seem poised to climb, as business momentum remains strong.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is opioid litigation and drug-pricing policy pressure.
high
opioid litigation and policy scrutiny
McKesson sits in the middle of the U.S. drug supply chain. That scale brings scrutiny. Litigation, settlement obligations, or tighter distribution rules can drain cash and add friction to a business built on volume.
the risk is not theoretical. It can hit both cash generation and operating freedom.
med
margin compression
Net margin is 1.2%. In plain English: there is almost no cushion. If reimbursement rates tighten, costs rise, or customer mix shifts the wrong way, a tiny change in spread matters a lot.
a 10 basis point margin hit on $470B revenue is roughly $470M of profit pressure.
med
specialty and GLP-1 normalization
Recent momentum has been helped by specialty medicines and $14B of GLP-1 volume. If that demand normalizes or mix shifts back toward lower-value distribution, earnings can slow even if revenue stays huge.
that would pressure the premium investors currently pay at 21.4x trailing earnings.
this is a sturdy company with a fragile margin structure. Half a trillion dollars of revenue does not protect you if the spread gets squeezed.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
net margin holding at 1.2%
This stock can absorb a lot of drama. It cannot absorb much margin erosion. If the 1.2% slips, the math changes fast.
calendar
Q4 FY2026 earnings call
Scheduled for May 7, 2026. You want to hear whether specialty demand and GLP-1 volume still support the raised full-year guide.
trend
specialty profit mix
Revenue scale is already there. The next question is whether oncology, multispecialty, and higher-value distribution keep making EPS grow faster than sales.
risk
policy and legal headlines
Drug-pricing action, distribution rules, and litigation updates matter here more than flashy product news. This is a regulated toll road.
Analyst rankings
earnings predictability
95 / 100
management usually lands close to where it guides. in human-speak, analysts trust the operating machine.
risk rank
1
this ranks among the safer stocks in the market. The business is dull in the best possible way.
price stability
95 / 100
the stock has been steadier than most. You are not buying a bunker, but you are not buying a rollercoaster either.
source: institutional data
Institutional activity
institutions have been net buying for 3 consecutive quarters — 785 buyers vs. 749 sellers in 3q2025. total institutional holdings: 0.1B shares. net buying for 3 quarters.
source: institutional data
Price targets
3-5 year target range
$696
$1364
$827
current price
$1055
target midpoint · +28% from current · 3-5yr high: $1160 (+40% · 9% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive